A Feasibility Trial of Sisterhood 2.0

A Gender Transformative Program to Prevent Sexual Violence and Relationship Abuse Among Adolescent Women: A Feasibility Trial of Sisterhood 2.0

This pilot quasi-experimental community based trial examines the feasibility of a sexual violence and adolescent relationship abuse prevention program for girls aged 14-19. Feasibility is assessed through participant attendance, retention and program satisfaction measures and interviews are conducted at baseline, end of program and 3 month follow up (endline) about participant experiences.

Study Overview

• Status: Completed
• Conditions: Violence, Domestic; Coping Skills; Violence in Adolescence; Adolescent Behavior; Violence, Sexual; Violence, Physical; Violence, Non-accidental; Group, Peer; Emotional Abuse; Communication, Personal
• Intervention / Treatment: Behavioral: Sisterhood 2.0

Detailed Description

The goal of the project is to adapt and pilot a "gender transformative," sexual violence and adolescent relationship abuse prevention program, Sisterhood 2.0, among African American high school-age females in a community-based setting. The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how these rigid stereotypes affect their health and well-being. This study will pilot test, using a quasi-experimental design, the participant satisfaction with the program through measures of attendance and retention, and be compared to a job skills development curriculum. This study is significant because there are too few evidence-based sexual violence and adolescent relationship abuse prevention program in the U.S., none that are specifically tailored for African American adolescent females, and there are no evidence- based programs implemented in community settings that target both sexual violence and adolescent relationship abuse and adolescent sexual health.

• Study Type: Interventional
• Enrollment (Actual): 246
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • University of Pittsburgh

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years to 19 years (ADULT, CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Participants must be ages 13-19 (inclusive)
• Participants must speak English
• Participants must self identify as female

Exclusion Criteria:

• Not ages 13-19 (inclusive)
• Does not speak English
• Does not identify as female

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Sisterhood 2.0; Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period. Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care.	Behavioral: Sisterhood 2.0; The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
ACTIVE_COMPARATOR: Job Skills Training; The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.	Behavioral: Sisterhood 2.0; The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participant Attendance	Attendance recorded at beginning and end of each session with a weekly satisfaction survey. Calculated as a proportion of total number of sessions.	through study completion, an average of 1 per week
Participant Retention	At the end of the program, participants were asked why they returned or did not return to the program each week and their reasons for missing any sessions.	post-intervention at Week 8
Participant Satisfaction	Participants were asked about how satisfied they were with the topic discussed and format of the program each week.	through study completion, an average of 1 per week

Collaborators and Investigators

• Sponsor: University of Pittsburgh
• Collaborators: The Grable Foundation; Department Human Services, Pennsylvania; Fisa Foundation

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 1, 2018
• Primary Completion (ACTUAL): June 1, 2019
• Study Completion (ACTUAL): January 31, 2020

Study Registration Dates

• First Submitted: May 11, 2020
• First Submitted That Met QC Criteria: May 11, 2020
• First Posted (ACTUAL): May 14, 2020

Study Record Updates

• Last Update Posted (ACTUAL): May 18, 2020
• Last Update Submitted That Met QC Criteria: May 14, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: PRO17010174

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The research team will not make individual participant data (IPD) available to other researchers. This plan to Share IPD is consistent with the IPD Sharing Plan Description for our collaborating agency.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No